Levothyroxine Sodium
- Product NDC
- 51655-985
- 11-digit product format
- 516550985
- Labeler code
- 51655
- Product ID
- 51655-985_4a28800d-14f1-d841-e063-6394a90a692b
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- Levothyroxine Sodium
- Dosage form
- TABLET
- Route
- ORAL
- Labeler
- Northwind Health Company, LLC
- Application
- ANDA209713
- Marketing category
- ANDA
- Marketing start
- 2022-05-04
- Substance
- LEVOTHYROXINE SODIUM
- Active strength
- .025 mg/1
- Pharmacologic classes
- Thyroxine [CS], l-Thyroxine [EPC]
- NDC exclude flag
- No
- Listing certified through
- 2027-12-31
- Current FDA listing
- Yes
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A209713-001 | LEVOTHYROXINE SODIUM | LEVOTHYROXINE SODIUM | 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | |
| A209713-002 | LEVOTHYROXINE SODIUM | LEVOTHYROXINE SODIUM | 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | |
| A209713-003 | LEVOTHYROXINE SODIUM | LEVOTHYROXINE SODIUM | 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | |
| A209713-004 | LEVOTHYROXINE SODIUM | LEVOTHYROXINE SODIUM | 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | |
| A209713-005 | LEVOTHYROXINE SODIUM | LEVOTHYROXINE SODIUM | 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | |
| A209713-006 | LEVOTHYROXINE SODIUM | LEVOTHYROXINE SODIUM | 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | |
| A209713-007 | LEVOTHYROXINE SODIUM | LEVOTHYROXINE SODIUM | 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | |
| A209713-008 | LEVOTHYROXINE SODIUM | LEVOTHYROXINE SODIUM | 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | |
| A209713-009 | LEVOTHYROXINE SODIUM | LEVOTHYROXINE SODIUM | 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | |
| A209713-010 | LEVOTHYROXINE SODIUM | LEVOTHYROXINE SODIUM | 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | |
| A209713-011 | LEVOTHYROXINE SODIUM | LEVOTHYROXINE SODIUM | 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | |
| A209713-012 | LEVOTHYROXINE SODIUM | LEVOTHYROXINE SODIUM | 0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 |
Therapeutic equivalence codes#
| Application-product | TE code |
|---|---|
| A209713-001 | AB1 |
| A209713-001 | AB2 |
| A209713-001 | AB3 |
| A209713-002 | AB1 |
| A209713-002 | AB2 |
| A209713-002 | AB3 |
| A209713-003 | AB1 |
| A209713-003 | AB2 |
| A209713-003 | AB3 |
| A209713-004 | AB1 |
| A209713-004 | AB2 |
| A209713-004 | AB3 |
| A209713-005 | AB1 |
| A209713-005 | AB2 |
| A209713-005 | AB3 |
| A209713-006 | AB1 |
| A209713-006 | AB2 |
| A209713-006 | AB3 |
| A209713-007 | AB1 |
| A209713-007 | AB2 |
| A209713-007 | AB3 |
| A209713-008 | AB1 |
| A209713-008 | AB2 |
| A209713-008 | AB3 |
| A209713-009 | AB1 |
| A209713-009 | AB2 |
| A209713-009 | AB3 |
| A209713-010 | AB1 |
| A209713-010 | AB2 |
| A209713-010 | AB3 |
| A209713-011 | AB1 |
| A209713-011 | AB2 |
| A209713-011 | AB3 |
| A209713-012 | AB1 |
| A209713-012 | AB2 |
| A209713-012 | AB3 |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | A209713-001 | LEVOTHYROXINE SODIUM | 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | A209713-002 | LEVOTHYROXINE SODIUM | 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | A209713-003 | LEVOTHYROXINE SODIUM | 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | A209713-004 | LEVOTHYROXINE SODIUM | 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | A209713-005 | LEVOTHYROXINE SODIUM | 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | A209713-006 | LEVOTHYROXINE SODIUM | 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | A209713-007 | LEVOTHYROXINE SODIUM | 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | A209713-008 | LEVOTHYROXINE SODIUM | 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | A209713-009 | LEVOTHYROXINE SODIUM | 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | A209713-010 | LEVOTHYROXINE SODIUM | 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | A209713-011 | LEVOTHYROXINE SODIUM | 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | A209713-012 | LEVOTHYROXINE SODIUM | 0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | A209713-001 | LEVOTHYROXINE SODIUM | 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | A209713-002 | LEVOTHYROXINE SODIUM | 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | A209713-003 | LEVOTHYROXINE SODIUM | 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | A209713-004 | LEVOTHYROXINE SODIUM | 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | A209713-005 | LEVOTHYROXINE SODIUM | 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | A209713-006 | LEVOTHYROXINE SODIUM | 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | A209713-007 | LEVOTHYROXINE SODIUM | 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | A209713-008 | LEVOTHYROXINE SODIUM | 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | A209713-009 | LEVOTHYROXINE SODIUM | 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | A209713-010 | LEVOTHYROXINE SODIUM | 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | A209713-011 | LEVOTHYROXINE SODIUM | 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | A209713-012 | LEVOTHYROXINE SODIUM | 0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | caaa826d4ba7… | |
| 2026-02-19 14:30 UTC | 2026-02 | A209713-001 | LEVOTHYROXINE SODIUM | 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | A209713-002 | LEVOTHYROXINE SODIUM | 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | A209713-003 | LEVOTHYROXINE SODIUM | 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | A209713-004 | LEVOTHYROXINE SODIUM | 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | A209713-005 | LEVOTHYROXINE SODIUM | 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | A209713-006 | LEVOTHYROXINE SODIUM | 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | A209713-007 | LEVOTHYROXINE SODIUM | 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | A209713-008 | LEVOTHYROXINE SODIUM | 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | A209713-009 | LEVOTHYROXINE SODIUM | 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | A209713-010 | LEVOTHYROXINE SODIUM | 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | A209713-011 | LEVOTHYROXINE SODIUM | 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | A209713-012 | LEVOTHYROXINE SODIUM | 0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A209713-001 | LEVOTHYROXINE SODIUM | 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A209713-002 | LEVOTHYROXINE SODIUM | 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A209713-003 | LEVOTHYROXINE SODIUM | 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A209713-004 | LEVOTHYROXINE SODIUM | 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | 31067a03dcf5… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | A209713-001 | AB1 | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A209713-001 | AB2 | 2 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A209713-001 | AB3 | 3 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A209713-002 | AB1 | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A209713-002 | AB2 | 2 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A209713-002 | AB3 | 3 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A209713-003 | AB1 | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A209713-003 | AB2 | 2 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A209713-003 | AB3 | 3 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A209713-004 | AB1 | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A209713-004 | AB2 | 2 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A209713-004 | AB3 | 3 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A209713-005 | AB1 | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A209713-005 | AB2 | 2 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A209713-005 | AB3 | 3 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A209713-006 | AB1 | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A209713-006 | AB2 | 2 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A209713-006 | AB3 | 3 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A209713-007 | AB1 | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A209713-007 | AB2 | 2 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A209713-007 | AB3 | 3 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A209713-008 | AB1 | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A209713-008 | AB2 | 2 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A209713-008 | AB3 | 3 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A209713-009 | AB1 | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A209713-009 | AB2 | 2 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A209713-009 | AB3 | 3 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A209713-010 | AB1 | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A209713-010 | AB2 | 2 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A209713-010 | AB3 | 3 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A209713-011 | AB1 | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A209713-011 | AB2 | 2 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A209713-011 | AB3 | 3 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A209713-012 | AB1 | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A209713-012 | AB2 | 2 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A209713-012 | AB3 | 3 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | A209713-001 | AB1 | 1 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | A209713-001 | AB2 | 2 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | A209713-001 | AB3 | 3 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | A209713-002 | AB1 | 1 | caaa826d4ba7… |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
Additional Listing Data#
- Finished product
- Yes
- Brand name base
- Levothyroxine Sodium
- Listing expiration
- 2027-12-31
Active Ingredients#
| Ingredient | Strength |
|---|---|
| LEVOTHYROXINE SODIUM | .025 mg/1 |
Harmonized UNII identifiers#
| Identifier | FDA.report destination |
|---|---|
| 9J765S329G | Internal UNII lookup |
Harmonized RxCUI identifiers#
| Identifier | FDA.report destination |
|---|---|
| 966220 | Internal RxNorm lookup |
Harmonized SPL set identifiers#
| Identifier | FDA.report destination |
|---|---|
| e0503b8c-7eb7-269e-e053-2995a90a1bca | Available on FDA.report |
DailyMed Product Concepts#
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| 97c252d3-9bb8-4530-bb44-9824dc7cf556 | Product name | 6 | 20250729 |
| 6c43b71c-35e6-4db3-ba24-c6ef42ff7003 | Product name | 3 | 20240207 |
| 890fd4bf-1a80-42b7-be1b-2d0259d5f0c8 | Product name | 5 | 20240207 |
| c8ad26bf-af73-460b-b74e-1eff16cc4f9f | Product name | 5 | 20240207 |
| 01383843-4069-43cf-aa76-dc17a6f9f8c4 | Product name | 2 | 20230123 |
| 978cca7d-a938-4791-8322-da48d90a63ef | Product name | 1 | 20230113 |
| 65f86ba3-8816-4e12-899b-18290c8de551 | Product name | 2 | 20210614 |
| f16ab90f-08c2-40be-a543-66d9827cd1f3 | Product name | 1 | 20210601 |
| 6a33ec05-2ae2-45e5-ab82-2d94b3303923 | Product name | 1 | 20190709 |
| 93355a10-1c44-4c92-a11d-7d995e0200d9 | Product name | 1 | 20190219 |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 51655-985-52 | Levothyroxine Sodium | 30 in 1 BOTTLE, PLASTIC | TABLET | 30 | 4 |
DailyMed Dashboard NDC Coverage#
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM | American Health Packaging | 38af4e36-b26b-485d-a6f3-7fbcf6072a0f | 2025-06-16 | Boxed warning, Warnings, Adverse reactions | 209713 ANDA209713 |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM | A-S Medication Solutions | f0680426-3581-400c-8ab5-5e6f18d0cabc | 2025-06-09 | Boxed warning, Warnings, Adverse reactions | 209713 ANDA209713 |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM | A-S Medication Solutions | b4654497-c986-4792-9b6b-0a791c7c205b | 2025-06-06 | Boxed warning, Warnings, Adverse reactions | 209713 ANDA209713 |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM | A-S Medication Solutions | 0e0ad9f1-1f52-48ce-a996-79ebe7ad53cd | 2025-06-06 | Boxed warning, Warnings, Adverse reactions | 209713 ANDA209713 |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM | A-S Medication Solutions | faaa1123-7515-46c2-abbb-b0615540c8cf | 2025-05-22 | Boxed warning, Warnings, Adverse reactions | 209713 ANDA209713 |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM | A-S Medication Solutions | 7f8ec438-8ddf-45d2-be94-ac032e192229 | 2025-05-19 | Boxed warning, Warnings, Adverse reactions | 209713 ANDA209713 |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM | A-S Medication Solutions | f5fc0f34-744c-4e03-ae9f-e017e4033139 | 2025-04-24 | Boxed warning, Warnings, Adverse reactions | 209713 ANDA209713 |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM | NuCare Pharmaceuticals, Inc. | 30ccec8b-3f95-61c7-e063-6394a90a05a0 | 2025-03-20 | Boxed warning, Warnings, Adverse reactions | 209713 ANDA209713 |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM | Lupin Pharmaceuticals, Inc. | 18717e58-89fb-4e2f-93b6-d6ac3e988d37 | 2025-03-19 | Boxed warning, Warnings, Adverse reactions | 209713 ANDA209713 |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM | Proficient Rx LP | f0a63075-631d-43bf-9d8e-df79faf0a278 | 2025-02-01 | Boxed warning, Warnings, Adverse reactions | 209713 ANDA209713 |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM | NuCare Pharmaceuticals, Inc. | 2cf48978-d996-f5ba-e063-6294a90a8824 | 2025-01-30 | Boxed warning, Warnings, Adverse reactions | 209713 ANDA209713 |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM | Bryant Ranch Prepack | ddec2148-f97e-4a79-9943-4bef2386a7f2 | 2025-01-21 | Boxed warning, Warnings, Adverse reactions | 209713 ANDA209713 |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM | NuCare Pharmaceuticals, Inc. | 27e98e6d-9fd7-3a94-e063-6394a90a1dcb | 2024-12-24 | Boxed warning, Warnings, Adverse reactions | 209713 ANDA209713 |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM | NuCare Pharmaceuticals,Inc. | 29bb8dbe-f8ba-e2ba-e063-6394a90af38c | 2024-12-20 | Boxed warning, Warnings, Adverse reactions | 209713 ANDA209713 |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM | Preferred Pharmaceuticals Inc. | a0ffe111-3574-4481-a732-b68a7d58ef71 | 2024-12-17 | Boxed warning, Warnings, Adverse reactions | 209713 ANDA209713 |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM | NuCare Pharmaceuticals, Inc. | 2646a481-09a5-af6a-e063-6394a90a16da | 2024-11-06 | Boxed warning, Warnings, Adverse reactions | 209713 ANDA209713 |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM | A-S Medication Solutions | 924bb6e9-4b2b-406f-a0a8-376b1f22f1f5 | 2024-10-14 | Boxed warning, Warnings, Adverse reactions | 209713 ANDA209713 |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM | NuCarePharmaceuticals, Inc. | 2380859a-5b65-f88f-e063-6394a90aa4e2 | 2024-10-02 | Boxed warning, Warnings, Adverse reactions | 209713 ANDA209713 |
| LEVOTHYROXINE SODIUM | LEVOTHYROXINE SODIUM | DIRECT RX | a5f15022-1166-09fe-e053-2a95a90aa218 | 2024-05-23 | Boxed warning, Warnings, Adverse reactions | 209713 ANDA209713 |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM | A-S Medication Solutions | 804d64c9-9804-4d6d-adb2-5036c0be8b5c | 2023-12-12 | Boxed warning, Warnings, Adverse reactions | 209713 ANDA209713 |
DailyMed RxNorm Mappings#
| RxCUI | RxNorm string | TTY | DailyMed | SPL version |
|---|---|---|---|---|
| 966220 | levothyroxine sodium 25 MCG Oral Tablet | PSN | e0503b8c-7eb7-269e-e053-2995a90a1bca | 4 |
| 966220 | levothyroxine sodium 0.025 MG Oral Tablet | SCD | e0503b8c-7eb7-269e-e053-2995a90a1bca | 4 |
| 966220 | levothyroxine sodium 25 MCG Oral Tablet | SY | e0503b8c-7eb7-269e-e053-2995a90a1bca | 4 |
Packages#
| Package NDC | 11-digit format | Description | Units | Marketing start | Marketing end | Sample | Exclude flag | Status |
|---|---|---|---|---|---|---|---|---|
| 51655-985-52 | 51655098552 | 30 TABLET in 1 BOTTLE, PLASTIC (51655-985-52) | 30 tablet | 2022-05-04 | 0000-00-00 | No | No | Current |